Tag: lung cancer
-
BioNTech’s Gotistobart Posts 18.5-Month Median Survival in Squamous NSCLC
Gotistobart achieved median overall survival of 18.5 months versus 10.0 months with docetaxel in the non-pivotal stage 1 portion of PRESERVE-003.
-
GSK Plans First-Line Jideytro Filing After 94% Response Rate
GSK plans to seek first-line FDA approval for Jideytro after the ROS1 inhibitor achieved a 94% response rate in 94 TKI-naïve patients in the ARROS-1 study.
-
GSK Licenses HUTCHMED’s HMPL-A830 in a Deal Worth Up to $1.295 Billion
GSK licensed HUTCHMED’s preclinical HMPL-A830 for up to $1.295 billion, gaining ex-Greater China rights to a KRAS-EGFR antibody-targeted therapy conjugate designed to combine EGFR-guided delivery with intracellular KRAS inhibition.